GLP1R and inflammatory bowel disease: Moreover, the rapid expansion of anti-obesity therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), bariatric surgery, and bariatric endoscopy, has outpaced the development of IBD-specific guidance(15–17).